Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow and Fair Value Hedging Relationships (Details) - USD ($) $ in Millions	3 Months Ended															12 Months Ended
	Dec. 31, 2020	[1]	Sep. 30, 2020	[2]	Jun. 30, 2020	[3]	Mar. 31, 2020	Dec. 31, 2019	[4]	Sep. 28, 2019	[5]	Jun. 29, 2019	[6]	Mar. 30, 2019	[7]	Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Net sales	$ 1,289.5		$ 1,213.7		$ 1,219.1		$ 1,341.0	$ 1,322.8		$ 1,191.1		$ 1,149.0		$ 1,174.5		$ 5,063.3	[8]	$ 4,837.4	[8]	$ 4,731.7	[8]
Cost of sales																3,248.1		3,064.1		2,900.2
Interest expense, net																131.2		121.7		128.0
Other (income) expense, net																17.2		(66.0)		$ 6.1
Foreign currency forward contracts | Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.2		2.5
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach																0.1		(2.1)
Foreign currency forward contracts | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																2.9		0.1
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach																1.1		(1.5)
Foreign currency forward contracts | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0		0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach																0.0		0.0
Foreign currency forward contracts | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0		0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach																0.5		0.0
Treasury locks | Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0		0.0
Treasury locks | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0		0.0
Treasury locks | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																(0.1)		(0.1)
Treasury locks | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0		0.0
Interest rate swap agreements | Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0		0.0
Interest rate swap agreements | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0		0.0
Interest rate swap agreements | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																(1.8)		(1.8)
Interest rate swap agreements | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																$ 0.0		$ 0.0

[1] Includes change in financial assets of $122.3 million and impairment charges of $144.4 million.

[2] Includes impairment charges of $202.4 million, change in financial assets of $22.2 million and loss on early debt extinguishment of $20.0 million.

[3] Includes Rosemont Pharmaceuticals business pre-tax loss of $21.1 million.

[4] Includes impairment charges of $141.6 million.

[5] Includes animal health divestiture pre-tax gain of $71.7 million, Ranitidine market withdrawal charges of $18.4 million, acquisition-related charges and contingent consideration adjustments of $18.1 million, and impairment charges of $10.9 million.

[6] Includes impairment charges of $27.8 million and restructuring charges and other termination benefits of $12.2 million.

[7] Includes change in financial assets of $10.4 million.

[8] The net sales by geography is derived from the location of the entity that sells to a third party.